Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely ...

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of ...

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier ...

A patient with highly aggressive primary acute mast cell leukemia (MCL), a rare subtype of systemic mastocytosis (SM), died 3 months after her diagnosis, according to a case report published ...

The FDA has accepted the sNDA for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant ...

Venetoclax (VEN) has shown excellent activity in eliminating acute myeloid leukemia (AML) blasts in preclinical and clinical trials, but clinical data in pediatric newly diagnosed AML (ND-AML) remain ...

Brittne Largent put off going to the doctor initially until her pain became unbearable. She thought she had Sciatica, but a trip to her physician led to a diagnosis of leukemia.

Background In patients presenting with acute coronary syndromes (ACS), impaired coronary blood flow (CBF) after percutaneous coronary interventions (PCI) is linked to mortality. We developed a novel ...